AZTR
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Azitra, Inc. (AZTR) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B+ (3.7) | D+ (1.8) | C (2.3) | D- (1.0) | C+ (2.6) | C (2.3) |
| 2026-11-10 | A- (3.9) | C- (1.9) | C (2.3) | D- (1.1) | C+ (2.6) | C (2.3) |
| 2026-11-03 | B+ (3.7) | D+ (1.8) | C (2.4) | D (1.3) | C+ (2.7) | C (2.4) |
| 2026-10-27 | C+ (2.5) | C- (1.9) | C (2.4) | C (2.3) | C+ (2.6) | C (2.3) |
| 2026-10-20 | B+ (3.7) | D+ (1.8) | C (2.4) | D (1.4) | C+ (2.6) | C (2.4) |